ResMed Inc (RMD), a $31.4 billion medical device company with an "GREAT" financial health rating according to InvestingPro, reported its Q3 FY2025 earnings, revealing a slight miss on earnings per ...

An auto CPAP machine will stay at a set pressure level while you fall asleep, then slowly increase throughout the night. Our favorite is the ResMed AirSense 10, a reliable model that has ...

In the US, we estimate roughly half of the 22 million people diagnosed with OSA are treated with continuous positive airway pressure, or CPAP ... ResMed and Philips reported selling over 10 ...

For example, the ResMed Airsense 11 line of full-sized units ... to be consistent with your sleep therapy. Skipping CPAP use while on your 10-day road trip in Europe because the machine is too ...

In its latest results released in late January, ResMed stated revenue increased by 10% for the quarter to US$1.3 billion. That was largely driven by increased demand for its sleep devices and ...

【Special Customized】This cpap carrying case is compatible with XT Fit, AirStart 10 and Phillips Dreamstation and accessories. Size: 16''L*6.5W*13H, CPAP compartment fits machines up to 15" x ...

We forecast margin expansion as ResMed’s sales mix continues to shift to higher-margin masks and cost inefficiencies of simultaneously producing its older AirSense 10 device cease ... positive airway ...

Given the high CPAP drop-out rate, this is significant ... Farrell notes strong demand for Resmed’s Airsense 10 device and the “market leading” Airsense 11. In the quarter, the company’s gross profit ...

Concerns over GLP-1 drugs reducing CPAP demand have diminished ... reassert the strong demand for ResMed product offerings, in particular AirSense 10 and the expanding AirSense 11 platforms.

For FY25, ResMed expects gross margins to be in the 59-60% range. Product Innovations and Growth Drivers ResMed's strong market position is underpinned by its innovative product portfolio. The company ...

Analysts project continued growth for ResMed, with FY25 revenue estimated at $5.14 billion and FY26 revenue at $5.53 billion. Corresponding EPS projections stand at $9.43 for FY25 and $10.51 for FY26.